Natera Inc Stock Price, News & Analysis

Natera, Inc. (NASDAQ: NTRA) announced that Centene has extended coverage for its Panorama non-invasive prenatal test (NIPT) to all pregnant women, including those with twins, impacting 24 million additional covered lives. The extension follows ACOG and SMFM's new guidelines supporting NIPT for all patients, regardless of age or risk. Natera's General Manager highlighted the significant growth potential in the under-penetrated average risk NIPT market due to expanded insurance coverage. Panorama is the only NIPT that differentiates between maternal and fetal DNA, analyzing risks for genetic disorders as early as nine weeks into pregnancy.

Natera, a leader in cell-free DNA testing, has partnered with the George Lopez Foundation for the #GLFTrickShot Challenge, a social media campaign aimed at raising awareness and funds for kidney patients. The initiative encourages participants to post videos of themselves making trick shots, linking them to a fundraising page for donations. The campaign addresses the concerning statistic that approximately 96% of individuals with early-stage kidney disease are unaware of their condition. Prominent celebrities are participating, highlighting the campaign's reach and impact.

Natera, Inc. (NASDAQ: NTRA) announced a significant legal victory as the U.S. District Court of Delaware dismissed all challenges from ArcherDX regarding Natera's patent infringement case. The court upheld the validity of Natera's patents related to cancer monitoring, affirming their eligibility under U.S. patent law. Natera continues to pursue its five-patent infringement lawsuit against ArcherDX, emphasizing its commitment to protecting its technology and intellectual property in oncology. With over 200 patents, Natera aims to advance cell-free DNA testing and enhance disease management globally.

Natera, a leader in cell-free DNA testing, announced that its Signatera test will be utilized in the DARE study, a Phase II clinical trial evaluating palbociclib (IBRANCE®) for treating early-stage HR-positive, HER2-negative breast cancer. The trial aims to enroll approximately 100 MRD-positive patients to assess the efficacy of palbociclib in second-line adjuvant therapy. Signatera will monitor patient eligibility and treatment effectiveness. This collaboration with Yale and Criterium/ABRCC highlights the potential of personalized MRD testing in improving cancer management.

Natera, Inc. (NASDAQ: NTRA) has received a draft local coverage determination (LCD) from CMS’s Molecular Diagnostics Program for expanded coverage of its Signatera circulating tumor DNA (ctDNA) test, which monitors minimal residual disease (MRD) in cancer patients. The LCD allows for coverage of Signatera in various solid tumors and builds on Medicare's recent colorectal cancer coverage decision. The Signatera test boasts a 100% positive predictive value for identifying treatment non-responders and can detect residual disease up to 2 years earlier than standard methods.

Natera (NASDAQ: NTRA) announced its participation in the 2020 European Society for Medical Oncology (ESMO) virtual meeting, where it will present new data on its personalized molecular residual disease (MRD) test, Signatera, from September 19-21, 2020. The company will showcase four abstracts, including one oral presentation and three posters, focused on MRD detection and tumor evolution in colorectal and esophageal cancers. Natera emphasizes that Signatera provides clinically actionable insights for managing solid tumors, enhancing monitoring and treatment decisions.

Natera, Inc. (NASDAQ: NTRA) has launched a program aimed at improving care for organ transplant patients with a history of cancer. This initiative utilizes the Signatera™ test for assessing molecular residual disease (MRD) and the Prospera™ test for monitoring transplant rejection. With a significant portion of transplant candidates having past cancer histories, the program seeks to establish data-driven guidelines for better patient management. Key studies include CONCERT for colorectal cancer patients and SIGNAL for liver cancer recurrence monitoring.

Natera, Inc. (NASDAQ: NTRA) announced that Noridian, the Medicare Administrative Contractor for Northern California, has approved Medicare benefits for the serial use of the Signatera molecular residual disease (MRD) test in colorectal cancer patients. This coverage determination aligns with a recent positive decision from the CMS Molecular Diagnostics program, effective October 18, 2020. The Signatera test, designed for personalized monitoring of cancer, has received FDA Breakthrough Device Designation and demonstrates high sensitivity in detecting residual disease.

Natera, Inc. (Nasdaq: NTRA) announced the pricing of its underwritten public offering of 4,166,666 shares at $60.00 per share, expected to close on September 15, 2020. The underwriters have a 30-day option to purchase an additional 624,999 shares. J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink serve as joint book-running managers. The offering follows an effective shelf registration statement filed with the SEC on September 9, 2020. Natera aims to innovate in cell-free DNA testing with a focus on women's health, oncology, and organ health.